FDA warns about non-GRAS cold products
This article was originally published in The Tan Sheet
Executive SummaryBoca Pharmacal markets OTCs containing prescription ingredients, making them products not generally recognized as safe and effective for use. In in a July 22 warning letter to the Coral Spring, Fla-based firm, FDA says the labels of the products - Pseudo DM GG Syrup and C-Phen DM Drops - suggest they diagnose, cure, mitigate, treat or prevent disease, although the drugs do not have approved applications. The agency adds the drugs are mislabeled for consumer use because the Rx ingredients are indicated for conditions that are not "amenable to self-diagnosis and treatment of individuals who are not medical practitioners." Boca, which contracted another firm to manufacture the products, has 15 days from receipt of the warning to notify FDA of its work to correct the violations and prevent a recurrence. The warning letter posted Sept. 20 on FDA's website does not identify the contract manufacturer
You may also be interested in...
Biodegradable plastic alternatives for use in cosmetic products were left unaddressed, and thus arguably unusable, under the US Microbead-Free Waters Act enacted in late 2015. European industry stakeholders now face the prospect of a far more extensive microplastic ban, and the viability of bioplastics to replace conventional, petroleum-based microplastics is an area in need of work.
Most of the foreign OTC drug firms targeted in latest warnings FDA published, including the GUM oral care brand manufacturer, were placed on import alert due to GMP violations. Each was inspected by FDA during June, July or May 2019, when the agency was wrapping up an initiative to inspect all previously uninspected drug manufacturers.
AstraZeneca will reacquire Allergan's investigational IL-23 inhibitor brazikumab, and Nestle is to buy its GI drug Zenpep, which had nine-month revenue of $208m.